Radiation Oncology

ALK+

Questions discussed in this category

How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?

Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?

1 Answer available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

2 Answers available

How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?

5 Answers available

Papers discussed in this category

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2024 Apr 11

Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2024 Jun 02

Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

Related Topics in Radiation Oncology